Skip to main content
John Leonard, MD, Oncology, New York, NY, New York-Presbyterian Hospital

JohnPLeonardMD

Oncology • New York, NY

Professor of Medicine, Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Cornell University-Weill Medical College

Request Appointment

Overview of Dr. Leonard

Dr. John Leonard is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, New York-Presbyterian Hospital, and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from University of Virginia School of Medicine and has been in practice 27 years. Dr. Leonard accepts several types of health insurance, listed below. He is one of 369 doctors at New York-Presbyterian Hospital and one of 115 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1993 - 1996
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1990 - 1993
  • University of Virginia School of Medicine
    University of Virginia School of MedicineClass of 1990

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License Current
  • NY State Medical License
    NY State Medical License 1991 - 2026
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
  • Elected Member The American Society for Clinical Investigation, 2009
  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Five-Year Follow-up of Lenalidomide plus Rituximab as Initial Treatment for Mantle Cell Lymphoma  
    Jia Ruan, Jakub Svoboda, John P Leonard, Sonali M Smith, Morton Coleman, Richard R Furman, Blood
  • CALBG 50604: Risk-Adapted Treatment of Non-Bulky Early Stage Hodgkin Lymphoma Based on Interim PET  
    David J Straus, Heiko Schoder, Bruce D Cheson, John C Grecula, Lale Kostakoglu, Eric D Hsi, Leslie L Popplewell, John P Leonard, Craig H Moskowitz, Brad S Kahl, Jonath..., Blood

Abstracts/Posters

  • Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)
    John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Continuing Medical Education and Patient Education on Follicular Lymphoma: Changes in Clinician Practice, Patient Behaviors, and Knowledge across Clinicians and Patients
    John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival i...
    John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Hodgkin Lymphoma: Genes to Microenvironment to Immunotherapy 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Realizing the Promise of Novel Therapeutics in NHL: A MasterClass and Tumor Board on Clinical Decision-Making in FL, MCL, and DLBCL 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Follicular Lymphoma: Have We Made Progress? 
    60th American Society of Hematology Annual Meeting - 12/3/2018
  • Join now to see all

Press Mentions

  • Dr. Sheila Nirenberg Wins Barbara McClintock Women Innovator Award
    Dr. Sheila Nirenberg Wins Barbara McClintock Women Innovator AwardJune 17th, 2022
  • LSS’ IMPACT—Hub & Spoke Clinical Trial Network for Blood Cancer-Based Clinical Research-as-a-care Option
    LSS’ IMPACT—Hub & Spoke Clinical Trial Network for Blood Cancer-Based Clinical Research-as-a-care OptionJuly 7th, 2021
  • Genentech and Leukemia & Lymphoma Society Award $1.3m to Weill-Cornell Medicine for Low-Income & Minority Access to Research as a Care Option
    Genentech and Leukemia & Lymphoma Society Award $1.3m to Weill-Cornell Medicine for Low-Income & Minority Access to Research as a Care OptionMay 13th, 2021
  • Join now to see all

Grant Support

  • Generation Of Kinase-Resistant NMDA Receptors By Gene-Targeting In The MouseNational Institute Of Neurological Disorders And Stroke2008–2009
  • Novel Monoclonal Antibody Therapies For LymphomaNational Center For Research Resources2001–2005
  • PH. II Trial/ Depsipeptide In Cutaneous T-Cell Lymphoma/ Relapsed PeripheralNational Center For Research Resources2004
  • Evaluation Of Functional Status, Quality Of Life, /Outcome /Older Lymphoma PTSNational Center For Research Resources2004
  • NMDA Receptor Modulation By Kinases--Molecular StudiesNational Institute Of Neurological Disorders And Stroke1998
  • Regulation Of NMDA Receptor ExpressionFogarty International Center1998

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    BCBS California PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    GHI PPO
    Great West PPO
    HIP of New York - Select PPO
    Humana ChoiceCare Network PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. John Leonard, Dr. John Leonard, MD, Dr. J Leonard, Dr. John P Leonard